Practise of Immunoglobulin Replacement Therapy in Primary and Secondary Immunodeficiencies: A Single Centre Experience from Malaysia

被引:0
|
作者
Zahari, Nurul Hidayah [1 ]
Abd Hamid, Intan Juliana [2 ,6 ]
Din, Sharifah Azdiana Tuan [1 ]
Hashim, Ilie Fadzilah [2 ]
Zainudeen, Zarina Thasneem [2 ]
Shariff, Noorsuzana Mohd [3 ]
Ahmad, Nor Hafizah [4 ]
Tay, Chan Yen [5 ]
机构
[1] Univ Sains Malaysia, Adv Med & Dent Inst, Dept Clin Med, Gelugor, Pulau Pinang, Malaysia
[2] Univ Sains Malaysia, Adv Med & Dent Inst, Dept Clin Med, Primary Immunodeficiency Dis Grp, Gelugor, Pulau Pinang, Malaysia
[3] Univ Sains Malaysia, Adv Med & Dent Inst, Hlth Community Dept, Gelugor, Pulau Pinang, Malaysia
[4] Natl Blood Ctr, Clin Transfus Dept, Kuala Lumpur, Malaysia
[5] Hosp Kuala Lumpur, Pharm Dept, Kuala Lumpur, Malaysia
[6] Univ Sains Malaysia, Adv Med & Dent Inst, Dept Clin Med, Primary Immunodeficiency Dis Grp, Kepala Batas 13200, Pulau Pinang, Malaysia
来源
MALAYSIAN JOURNAL OF MEDICAL SCIENCES | 2023年 / 30卷 / 03期
关键词
intravenous immunoglobulin; off-labelled indication; hypogammaglobulinemia; chronic inflammatory demyelinating polyneuropathy; primary immunodeficiencies; INTRAVENOUS IMMUNOGLOBULIN; PEDIATRIC POPULATION; IVIG;
D O I
10.21315/mjms2023.30.3.10
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Intravenous immunoglobulin (IVIG) replacement therapy is increasingly in demand. This study focused on the characteristics of IVIG usage and associated factors toward the frequency status of IVIG among patients in Hospital Kuala Lumpur. Methods: A retrospective cross-sectional study was performed on patients who received IVIG in Hospital Kuala Lumpur. Data were extracted from the request forms for IVIG recorded in the Pharmacy Department from January 2018 until December 2019. Chi-squared test and t-test analysis were used for statistical analysis, and a P-value of < 0.05 was considered significant. Results: A total of 482 patients received IVIG in Hospital Kuala Lumpur. There were 243 (50.4%) females and 228 (47.3%) males with median age of the patients was 27 years old. The highest indications for IVIG among all patients were hypogammaglobulinemia and other deficiency states in 127 patients (26.3%). The most common indication for one-off treatment in adults was hypogammaglobulinemia and other deficiency states, 35%; whereas in paediatrics, it was Kawasaki disease, 20.3%. The highest indication for regular therapy among adult patients was chronic inflammatory demyelinating polyneuropathy (23.4%), while in paediatrics it was sepsis (31.1%). The clinical category was associated with the frequency status of IVIG usage in both adult and paediatric cohorts with P = 0.004 and P = 0.017, respectively. Conclusion: There were significant differences between the indication of one-off treatment and regular therapy among adult and paediatric patients. A national guideline on the prescription of IVIG for patients is instantly needed to help clinicians in prescribing IVIG appropriately.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 50 条
  • [31] Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
    William C Gerth
    Stephen D Betschel
    Arthur S Zbrozek
    Allergy, Asthma & Clinical Immunology, 10 (Suppl 1)
  • [32] Primary hyperoxaluria type 1 in children: Clinical classification, renal replacement therapy, and outcome in a single centre experience
    Fadel, Fatina I.
    Kotb, Magd A.
    Abdel Mawla, Mohamed A.
    Hasanin, Rasha M.
    Salem, Amr Mohamed
    Fathallah, Mohamed Gamal
    Amr, Khalda Sayed
    Ahmed, Hoda Abdalla
    Salah, Doaa M.
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (01) : 162 - 170
  • [33] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    Gerth, William C.
    Betschel, Stephen D.
    Zbrozek, Arthur S.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2014, 10
  • [34] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    William C Gerth
    Stephen D Betschel
    Arthur S Zbrozek
    Allergy, Asthma & Clinical Immunology, 10
  • [35] Immunoglobulin Supplementation Therapy - One Centre Experience
    Tepla, I.
    Cerna, S.
    Krcmova, I.
    Kralickova, P.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S512 - S512
  • [36] Thrombosis Association with Administration of Intravenous Human Immunoglobulin in Patients with Primary or Secondary Immunodeficiencies
    Goncalves, Danilo Gois
    de Assis, Joao Paulo
    Sini, Bruno
    Marinho, Ana Karolina
    Kokron, Cristina Maria
    Grecco, Octavio
    Kalil, Jorge
    Barros, Myrthes Toledo
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S55 - S55
  • [37] Adverse Reactions of Intravenous Immunoglobulin Replacement Therapy in Primary Immune Deficient Patients; A 12 Year Experience of a Single Center
    Camcioglu, Y.
    Ozek, E.
    Cokugras, H.
    Akcakaya, N.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S278 - S278
  • [38] Subcutaneous immunoglobulin replacement therapy: the European experience
    Chapel, Helen
    Gardulf, Ann
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 13 (06) : 623 - 629
  • [39] ADVERSE REACTION WITH INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY AND MANAGEMENT OF SYMPTOMS: A SINGLE CENTRE EXPERIENCE
    Wildman, Sabina H. A.
    Al-Obaidi, Muthana
    RHEUMATOLOGY, 2020, 59
  • [40] Outcomes of a patient support programme for subcutaneous immunoglobulin therapy in patients with primary or secondary immunodeficiencies or chronic inflammatory demyelinating polyneuropathy
    Crispin, Philip
    Henderson, Robert
    Yun, James
    Crosbie, Christina
    Tognarini, David
    Youssef, Sherif
    Barrese, Giulio
    Fleischmann, Simone
    INTERNAL MEDICINE JOURNAL, 2024, 54 (11) : 1827 - 1837